New York, NY – April 2, 2018 – Maxim Group LLC, a leading full service investment banking, securities and wealth management firm today announced the enhancement of its Healthcare Equity Research practice with the promotion of Dr. Jason McCarthy, Ph.D. to Senior Managing Director of Biotechnology.
“Maxim Group continues to build one of the premier proprietary research platforms on Wall Street, with an emphasis on emerging growth and paradigm-shifting businesses. Biotechnology is an important vertical in our healthcare practice and we are proud to have Jason leading this effort,” said Anthony V. Vendetti, Executive Managing Director of Research for Maxim Group. The biotechnology team currently covers over 50 research names and expects to double research coverage over the next year as more resources are added to build out this important vertical.
In his expanded role, Dr. McCarthy will work with Anthony Vendetti in the development and implementation of Maxim Group’s biotechnology research strategy with a key focus on product expansion on the Institutional and Wealth Management platforms. Dr. McCarthy received his doctoral degree in Biomedical Research (Albert Einstein College of Medicine) and Molecular Biology (Adelphi University), as well as a B.S. in Biochemistry from Stony Brook University.
Michael Rabinowitz, Chairman & CEO of Maxim Group, added “Our commitment to build a first class healthcare practice has never wavered, and Dr. McCarthy’s well-deserved promotion is another significant step in that process. As we continue our firm-wide expansion, we expect to add other high quality professionals to the Maxim Group Research team.”